Monoclonal antibody imaging in the management of recurrent ovarian cancer

R. A. Lawhead, H. T. Williams

Research output: Contribution to journalArticlepeer-review


More than 65% of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.

Original languageEnglish (US)
Pages (from-to)67-72,74
JournalFemale Patient - OB/GYN Edition
Issue number12
StatePublished - Dec 1 1995
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Monoclonal antibody imaging in the management of recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this